Obermatt
See Similar Stocks →

Vir Biotechnology

NSQ:VIR · US92764N1028
BiotechnologyMedium

360

56
Profit price19
Owner Earnings Yield1
Dividend Yield1
Price/Sales82
Price/Book67
Return on Capital37
Cash Return on Capital32
Return on Equity39
Profit margins7
Accruals74
Owner Earnings Margin15
Sales growth95
Profit growth27
Reinvestment75
Price momentum65
Debt load38
Refinancing43
Debt Payback1
Liquidity83
Analyst ratings45
Opinion Changes50
Price Target Upside94
Market mood17
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Vir Biotechnology doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded2016
Employees431
Websitevir.bio
ISINUS92764N1028
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyInfectious DiseasesArtificial IntelligenceHepatologyVaccinesRespiratoryOncologyBiopharmaBiotechnologyHealth CareMedical

Description

Vir Biotechnology, Inc. (Vir) operates as a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. The company’s clinical…

Analysis

Middle-of-the-road

Vir Biotechnology, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is solid; the safety picture is adequate. The company scores 6/20 on our value-creation score: not creating value. Analysts lean positive.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
76
2026

All-time high

77

Mar 2026

All-time low

76

Jun 2026

Average rank

77

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
82
—
—
—
Price/Earnings
62
—
—
—
Price/Book
67
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
77
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Vir Biotechnology with its peers
Celcuity
NAQ:CELC
96
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sellas Life Sciences
NAQ:SLS
62
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Atea Pharmaceuticals
NSQ:AVIR
5
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Kymera Therapeutics
NMQ:KYMR
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Crescent Biopharma
NAQ:CBIO
19
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Lexeo Therapeutics
NMQ:LXEO
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →